Anti-Cardiac Troponin I antibody [4C2] (ab10231)
Key features and details
- Mouse monoclonal [4C2] to Cardiac Troponin I
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG2a
Overview
-
Product name
Anti-Cardiac Troponin I antibody [4C2]
See all Cardiac Troponin I primary antibodies -
Description
Mouse monoclonal [4C2] to Cardiac Troponin I -
Host species
Mouse -
Specificity
reacts with free cardiac troponin I (cTnI) and cTnI forming complexes with other troponin components (in the presence of 5 mM EDTA). Not affected by heparin, phosphorylation, oxidation and troponin complex formation. Does not cross-react with skeletal muscle troponin I. -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length native protein (purified) corresponding to Human Cardiac Troponin I.
-
Epitope
23-29 aa -
General notes
Concentration varies from lot to lot and can be provided on request.The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Protein A purified -
Purification notes
Purity tested by electrophoresis. -
Clonality
Monoclonal -
Clone number
4C2 -
Myeloma
Sp2/0 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab10231 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (1) |
Use a concentration of 1 µg/ml.
|
Notes |
---|
IHC-P
Use a concentration of 1 µg/ml. |
Target
-
Function
Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. -
Involvement in disease
Defects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. -
Sequence similarities
Belongs to the troponin I family. - Information by UniProt
-
Database links
- Entrez Gene: 7137 Human
- Omim: 191044 Human
- SwissProt: P19429 Human
- Unigene: 709179 Human
-
Alternative names
- cardiac muscle antibody
- Cardiac troponin I antibody
- cardiomyopathy, dilated 2A (autosomal recessive) antibody
see all
Images
-
Ab10231 staining human heart tissue. Staining is localised to cytoplasm.
Left panel: with primary antibody at 1ug/ml. Right panel: isotype control.
Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 antigen retrieval buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
Datasheets and documents
-
SDS download
-
Datasheet download
References (24)
ab10231 has been referenced in 24 publications.
- Boye C et al. Reduction of plasmid vector backbone length enhances reporter gene expression. Bioelectrochemistry 144:107981 (2022). PubMed: 34847374
- Ribeiro MC et al. A New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues. J Pers Med 12:N/A (2022). PubMed: 35207702
- Schuldt M et al. Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes. J Mol Cell Cardiol 150:77-90 (2021). PubMed: 33148509
- Boye C et al. Cardioporation enhances myocardial gene expression in rat heart. Bioelectrochemistry 142:107892 (2021). PubMed: 34371349
- Sayed N et al. miRNA transfection via poly(amidoamine)-based delivery vector prevents hypoxia/reperfusion-induced cardiomyocyte apoptosis. Nanomedicine (Lond) 15:163-181 (2020). PubMed: 31799897